Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Lisata Therapeutics Inc.
Headquarters: Basking Ridge, NJ, United States of America
Website: https://www.lisata.com/
Year Founded: 2006
Status: Public
Industry Sector: HealthTechnology
CEO: David J. Mazzo, PhD
Number Of Employees: 26
Enterprise Value: $-6,541,580
PE Ratio: -0.97
Exchange/Ticker 1: NASDAQ:LSTA
Exchange/Ticker 2: N/A
Latest Market Cap: $19,998,800
BioCentury | Mar 10, 2025
Deals
Sun takes shine to Checkpoint in $355M buyout: Deals Report
Plus: Jazz acquires Chimerix for 72% premium, and J&J does not exercise HexaBody Genmab option, Myokardia ends partnership with Fulcrum
BioCentury | Aug 16, 2023
Regulation
Aug. 15 Quick Takes: April PDUFA for Carvykti in earlier stage MM
Plus: Nucleic acid company Impilo launches to treat solid tumors and updates from Galecto, Design, Arcellx, Amicus, Alaunos, Lidao
BioCentury | Apr 28, 2022
Finance
April 27 Quick Takes: Singapore mRNA play RVAC debuts with $140M
Plus Amgen pushes back on the IRS, Caladrius, Cend merge and updates from BeiGene, Roche and more
Items per page:
1 - 3 of 3